Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

Affiliation auteurs!!!! Error affiliation !!!!
TitreClinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
Type de publicationJournal Article
Year of Publication2020
AuteursPistilli B, Wildiers H, Hamilton EPaige, Ferreira AAlexandra, Dalenc F, Vidal M, Gavila J, Goncalves A, Murias C, Mouret-Reynier M-A, Canon J-LRe, Bazan F, Ladoire S, L. Sirulnik A, Bekradda M, Bol K, Stalbovskaya V, Murat A, Ford J, Bidard FClement
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X